

**Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes**

Date: April 18, 2024

Chairperson: not yet elected

Erin Halverson, Iowa Medicaid staff, assisted in running the meeting as the last chairperson was not re-appointed to the committee for this term. Elections took place at this meeting as shown below.

Time: 9:30 a.m. to 12:02 p.m.

Location: Grimes State Office Building Room B100, 400 E 14th Street, Des Moines, IA 50319

Committee Members Present: Charles Wadle, D.O.; Jason Kessler, M.D.; Lacey Ferguson, Pharm.D.; Rachel Kinn, Pharm.D.; Tricia White, R.N.; and Jason Kruse, D.O. (Vacancies July 2023: 1 Physician, 1 Physician Assistant)

Iowa DHHS Staff Present: Abby Cate, Pharm.D., Pharmacy Consultant; Jenny Erdman, LMHC, Bureau Chief for Medicaid Quality Innovation and Medical Policy; and Darian Forcier, Pharmacy Administrative Support.

Iowa Medicaid Staff Present: Jacquelyn Hedlund, M.D., MS; Paige Clayton, Pharm.D.; Erin Halverson, R.Ph.; Gina Kuebler, R.Ph.; and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Jordan Thoman, Wellpoint Iowa; Carroll Nelson, Iowa Total Care; and Candace Jordan, Molina Healthcare of Iowa.

Erin Halverson called the meeting to order.

- I. Erin Halverson asked that each committee and DHHS/Medicaid staff member introduce themselves to the public. Jason Kruse made the motion to approve the November minutes, and Rachel Kinn seconded. The motion passed with no objections. There were no new verbal conflict of interest disclosures.
- II. Annual P&T Committee Chairperson and Vice Chairperson Elections: Rachel Kinn nominated Jason Kruse for Chairperson. Chuck Wadle seconded, and all members were in favor. Jason Kruse then nominated Chuck Wadle as Vice Chairperson. He accepted, and this decision was also unanimous.
- III. PDL Revision Notifications (Erin Halverson): The fax blasts sent to providers since the last P&T Meeting in November, to notify them of preferred drug list changes, were reviewed. Due to the continued transition of naloxone hydrochloride nasal liquid to over-the-counter status, OTC naloxone hydrochloride 4 mg/0.1 mL nasal liquid will become preferred on the PDL. Sirolimus oral solution will also be preferred, due to the discontinuation of Rapamune oral solution.
- IV. Drug Rebate Issues (Dr. Clayton): Change Healthcare is monitoring the effect of the AMP cap removal effective in January 2024, as PDL changes could arise due to manufacturers' responses

to that change. There has already been a lot of price fluctuation across the board on brand name drugs as anticipated, as well as the “penny” older generic drugs. The CMS pricing file is set to be released in three weeks.

- V. PA Criteria/Pro-DUR Edits (Dr. Cate): Committee members were provided copies of the informational letters sent to providers since the last meeting, most of which pertained to the Change Healthcare cyber attack and resulting system outages, explained in further detail below in the Medicaid updates section.
- VI. Legislation (Dr. Cate): Legislative bills that would affect Iowa Medicaid and the pharmacy benefit include one for the modernization of the Pharmacy Practice Act, regulation of pharmacy benefit managers, 340b drug prices, pharmacist use of epinephrine, pharmacist prescribing of hormonal contraceptives, and pharmacist or practitioner judgement. Two bills are still being considered. House File 555, which updates Iowa’s Pharmacy Practice Act to reflect current training and education for Iowa’s pharmacists, has passed and is awaiting the governor’s signature. House File 2401, related to the pharmacy benefit manager reform, has not passed yet, but is still eligible for a possible vote in the Senate.
- VII. Iowa Medicaid Updates (Dr. Cate): Managed care organization Amerigroup has now changed their name to Wellpoint Iowa as of January 1, 2024. A cost of dispensing survey will go out to providers in May, with responses due back in August. Iowa Medicaid received approval to move forward with a rule change to allow a 90-day supply per prescription, rather than the 31 days currently allowed. A 90-day allowance was implemented during the Public Health Emergency (PHE), and had a positive impact on the pharmacy program, as well as the members. The DUR Commission reviewed and recommended a re-implementation of the 90-day supply limit for certain reviewed drugs, mostly generic maintenance medications, not all PDL medications like during the PHE. The Change Healthcare cyber attack did affect the pharmacy fee-for-service program. The Point-of-Sale systems, including eligibility look-up, prior authorization, and billing applications, were unavailable from February 21, 2024 to March 28, 2024. The prior authorization mandates and refill too soon edits were removed during that time span, but are now back in place for dispensing dates after March 28, 2024.
- VIII. Public Comment: In addition to the written public comments provided to committee members, they heard oral public comment from the speakers shown below. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

Name	Representing	Drug/Topic
Sanjay Lalbahadur	Indivior	Opvee
Tami Sova	Biogen	Skyclarys and Zurzuvae
Lori Showalter	UCB	Bimzelx
Cari Chestnut	Novartis	Fabhalta
Amy Hornig	Abbvie	Rinvoq

Member Comments Received: Skyclarys

Provider Comments Received: Skyclarys, Bimzelx

Manufacturer Comments Received: Xdemvy, Entyvio, Zilbrysq, Skyclarys, Agamree

At 10:05, Chuck Wadle motioned to go to closed session as authorized by Iowa Code Section 21.5(1)(a) of the Open Meetings Law to review or discuss economic records associated with the PDL which are required or authorized to be kept confidential, and the motion passed with unanimous roll call approval. Open session resumed at 11:05.

IX. PDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 2) were made to maximize cost savings to the program unless otherwise noted.

1. Dupixent to Preferred with Conditions.
2. Emgality to Preferred with Conditions.
3. Lubiprostone to Preferred with Conditions (due to discontinuation of Amitiza).
4. Prednisolone tablets to Non-Preferred.
5. Skytrofa to Preferred with Conditions after step through one preferred short acting growth hormone product.
6. Opvee to Preferred.

Jason Kruse motioned to accept the recommendations above, and Rachel Kinn seconded. The decision was unanimous.

The drugs listed below are recommended to be removed from coverage under the pharmacy benefit, as they are intended to be administered in a healthcare/office setting (coverage and billing is available through the medical benefit):

1. Eligard
2. Lupron Depot
3. Lupron Depot-PED
4. Trelstar

Jason Kessler motioned to accept the recommendations above, and Lacey Ferguson seconded. The decision was unanimous.

X. RDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 3) were made to maximize cost savings to the program unless otherwise noted.

1. Afinitor tablets to Non-Preferred with Conditions.
2. Everolimus tablets to Preferred with Conditions.

Rachel Kinn motioned to accept the recommendation above, and Tricia White seconded. The decision was unanimous.

XI. Newly Released Drugs (Dr. Hedlund and Erin Halverson): All following recommendations (with numbering as provided on agenda attachment 4) were made to maximize cost savings to the

program unless otherwise noted. Dr. Hedlund reviewed the clinical information for the new drugs, and then Erin Halverson read through the recommendations as follows:

1. Agamree- Recommend status on the PDL as Non-Preferred
2. Akeega- Recommend status on the RDL as Non-Recommended with Conditions
3. Augtyro- Recommend status on the RDL as Non-Recommended with Conditions
4. Bimzelx- Recommend status on the PDL as Non-Preferred with Conditions
5. Fabhalta- Recommend status on the PDL as Non-Preferred
6. Fruzaqla- Recommend status on the RDL as Non-Recommended with Conditions
7. Iwilfin- Recommend status on the RDL as Non-Recommended with Conditions
8. Ojjaara- Recommend status on the RDL as Non-Recommended with Conditions
9. Omvoh Auto-Injector- Recommend status on the PDL as Non-Preferred with Conditions
10. Skyclarys- Recommend status on the PDL as Non-Preferred
11. Sohonos- Recommend status on the PDL as Non-Preferred
12. Truqap- Recommend status on the RDL as Non-Recommended with Conditions
13. Velsipity- Recommend status on the PDL as Non-Preferred with Conditions
14. Wainua- Recommend status on the PDL as Non-Preferred
15. Xdemvy- Recommend status on the PDL as Non-Preferred
16. Xphozah- Recommend status on the PDL as Non-Preferred
17. Zilbrysq- Recommend status on the PDL as Non-Preferred
18. Zurzuvae- Recommend status on the PDL as Non-Preferred

Jason Kruse motioned to accept the recommendations above, and Jason Kessler seconded. The decision was unanimous.

XII. Newly Released Generic Drugs (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Adalimumab aacf	Non-Preferred with Conditions
Adalimumab adbm	Non-Preferred with Conditions
Amphetamine- Dextroamphetamine 3- Bead Cap ER	Non-Preferred with Conditions
Cyanocobalamin Spray	Non-Preferred
Dapagliflozin	Non-Preferred with Conditions
Dapagliflozin and Metformin	Non-Preferred with Conditions
Dextroamphetamine Sulfate Tabs	Non-Preferred with Conditions (5mg & 10mg remain Preferred)
Fluticasone Propionate BA	Non-Preferred
Insulin Glargine 300 units/mL	Non-Preferred
Insulin Glargine Yfgn	Non-Preferred
Pazopanib	Non-Preferred with Conditions
Pitavastatin	Non-Preferred

Risperidone Injection	Non-Preferred Step 3
Spironolactone Oral Suspension	Non-Preferred

Chuck Wadle motioned to accept the recommendations above. Rachel Kinn seconded, and all members were in favor.

XIII. New Drug Dosage Forms/Strengths/Combinations/BioSimilar (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Abrilada	Non-Preferred with Conditions
Cabtreo	Non-Preferred with Conditions
Cuvrior	Non-Preferred
Entyvio Subcutaneous Pen Injector	Non-Preferred with Conditions
Furoscix	Non-Preferred
Jylamvo	Non-Preferred
Likmez	Non-Preferred with Conditions
Motpoly XR	Non-Preferred with Conditions
Nitrofurantoin Oral Suspension 50mg/5mL	Non-Preferred
Olpruva	Non-Preferred
Rykindo	Non-Preferred Step 3
Suflave	Non-Preferred
Tramadol 25mg Tab	Non-Preferred with Conditions
Valsartan Oral Solution	Non-Preferred with Conditions
Veveye	Non-Preferred
Zituvio	Non-Preferred with Conditions

Jason Kruse motioned to accept the recommendations above. Jason Kessler seconded, and all members were in favor.

A motion was made by Jason Kessler to adjourn the meeting. It was seconded by Chuck Wadle, and all in attendance approved. The meeting adjourned at 12:02 p.m. The next scheduled meeting is set for August 15, 2024.